INSTRUCTIONS: Please type or print in ink. Please read carefully the attached instructions and supply the information requested on this form. Use additional sheet(s) if necessary.

1. Company Name and Address4. EPA ProductRegistration

United States Environmental Protection

Agency Washington, D.C. 20460

DATA CALL-IN RESPONSE

3. Date and Type of DCI 

GENERIC12-May-2010ID # GDCI-08330

2. Case # and Name

3074 Grotan (*)Chemical # and Name 083301

Hexahydro-1,3,5-tris(2-hydroxyethyl)-s-triazine

5. I wish to cancel this product registration voluntarily

6. Generic Data 7. Product Specific Data

7a. My product is an MUP andI agree to satisfy the MUP requirements on the attached form entitled "Requirements Status and Registrant's Response."

6a. I am claiming a GenericData Exemption because I obtain the active ingredient from the source EPA registration number listed below.

6b. I agree to satisfy Generic Data requirements as indicated on the attached form entitled "Requirements Status and Registrant's Response."

N.A. 

10. Name of Company 11. Phone Numb

9. Date 8. Certification I certify that the statements made on this form and all attachments are true, accurate, and complete. I acknowledge that any knowingly false or misleading statement may be punishable by fine, imprisonment or both under applicable law.

Signature and Title of Company's Authorized Representative__________________________________
Hexahydro-1,3,5-tris(2-hydroxyethyl)-s-triazine

INSTRUCTIONS: Please type or print in ink. Please read carefully the attached instructions and supply the information requested on this form. Use additional sheet(s) if necessary.

4. Guideline Requirement Number

5. Study Title

1. Company Name and Address

United States Environmental Protection

Agency Washington, D.C. 20460

REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE

3. Date and Type of DC

ID #GENERIC12-May-2010

GDCI-08330

2. Case # and Name

3074 Grotan (*)

Chemical # and Name 083301

7. Test Substance

6. Use Pattern

P

R

O

T

O

C

O

L

Progress

Reports

1 2 3

Applicator Exposure Data Requirements (Antimicrobial)

875.1100 Dermal exposure--outdoor (22 ,23 ,24) M, X 875.1200 Dermal exposure--Indoor (25 ,26 ,27) M, X 875.1300 Inhalation exposure--outdoor (28 ,29 ,30) M, X 

(31 ,32 ,33,34)

875.1400 Inhalation exposure--indoor M, X 875.1600 Application exposure monitoring data reporting (35 ,40) M, X 875.1700 Product Use Information (38) M, X 

Post-Application Exposure Data Requirements (ConventionalChemical)

875.2900 Data reporting and calculations (37) M, X 

Postapplication Exposure Data Requirements (Antimicrobial)

875.2800 Description of human activity (36) M, X 875.2700 Product Use Information (39) M, X 

12. Name of Company 13. Phone NumbSignature and Title of Company's Authorized Representative__________________________________10. Certification I certify that the statements made on this form and all attachments are true, accurate, and complete. I acknowledge that any knowingly false or misleading statement may be punishable by fine, imprisonment or both under applicable law

11. Date
Hexahydro-1,3,5-tris(2-hydroxyethyl)-s-triazine

INSTRUCTIONS: Please type or print in ink. Please read carefully the attached instructions and supply the information requested on this form. Use additional sheet(s) if necessary.

4. Guideline Requirement Number

5. Study Title

1. Company Name and Address

United States Environmental Protection

Agency Washington, D.C. 20460

REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE

3. Date and Type of DC

ID #GENERIC12-May-2010

GDCI-08330

2. Case # and Name

3074 Grotan (*)

Chemical # and Name 083301

7. Test Substance

6. Use Pattern

P

R

O

T

O

C

O

L

Progress

Reports

1 2 3

Toxicology Data Requirements (Antimicrobial)

870.1300 Acute inhalation toxicity (1 ,2 ,3 ,4) M, X MP; TGAI/MP 870.3150 90-day oral toxicity in nonrodents (5 ,6 ,7) M, X TGAI 870.3465 90-day inhalation toxicity (8) M, X TGAI 870.3700 Prenatal developmental toxicity study (9 ,10 ,11) M, X TGAI 870.3800 Reproduction and fertility effects (12 ,13) M, X TGAI 

(14 ,15 ,16,17)

870.4100 Chronic toxicity M, X TGAI 

(18 ,19 ,20,21)

870.4200 Carcinogenicity M, X TGAI 

Initial to indicate certification as to information on this page (fulltext of certification is on page one).

Date
Case # and Name: 3074 Grotan (*)

DCI Number: GDCI-083301-29711

Footnotes: [The following notes are referenced in column two (5. Study File) of the REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE form.]Key:

United States Environmental Protection

Agency Washington, D.C. 20460

FOOTNOTES AND KEY DEFINITIONS FOR GUIDELINE REQUIREMENTS

MP; TGAI = Manufacturing Use Product; Technical Grade Active Ingredient; MP = Manufacturing Use Product [MP]; TGAI = Technical Grade Active Ingredient 

Use Categories Key:

M - X - 

Indoor nonfood useMaterials preservatives

1 For the six acute studies conducted with the end-use product, the test must be conducted using the product as formulated for sale and distribution. If the 

diluted for use, the applicant may also wish to conduct certain studies using the highest diluted concentration (i.e. lowest dilution rate) permitted by the la

2 Required when the product consists of, or under conditions of use will result in, an inhalable material (e.g., gas, vapor, aerosol or particulates).

3 The 870 series studies for the MP and EP are intended to provide data on the acute toxicity of the product. Waivers for any or all of these studies may be 

demonstrate that the combination of inert ingredients is not likely to pose any significant human health risks. Where appropriate, the limit dose approach 

4 Required when the product consists of, or under conditions of use will result in, an inhalable material (e.g. gas, volatile substances, or aerosol particulate5 The 90-day dermal toxicity study or 90-day inhalation toxicity study may be substituted for the 90-day oral toxicity study if it is determined that dermal or 

exposure.

6 The 90-day oral toxicity test in nonrodents may be required when the use of the antimicrobial pesticide is likely to result in repeated human exposure ove

lifespan, as determined by the Agency, or when the use requires a tolerance or exemption from the requirement for a tolerance.

7 This test is required for low-exposure indirect food uses.8 Required if the active ingredient is a gas at room temperature or if the Agency determines that use of the product may result in repeated inhalation expos

regardless of whether the major route of exposure is inhalation.

9 The test substance must be administered orally or by gastric intubation.10 The test substance must be administered orally or by gastric intubation.11 When a pesticide is determined to be a developmental toxicant after oral dosing and dermal exposure is determined by the Agency to be significant, add

be required to determine whether the pesticide poses a risk of developmental toxicity through dermal exposure.

12 A two-generation reproduction study is required.

13 Required for low exposure uses if use of the antimicrobial pesticide product is likely to result in significant human exposure, as determined by the Agency

or duration of the exposure.

14 The 90-day oral toxicity test in nonrodents may be required when the use of the antimicrobial pesticide is likely to result in repeated human exposure ove

lifespan, as determined by the Agency, or when the use requires a tolerance or exemption from the requirement for a tolerance.

15 The 90-day oral toxicity test in nonrodents may be required when the use of the antimicrobial pesticide is likely to result in repeated human exposure ove

lifespan, as determined by the Agency, or when the use requires a tolerance or exemption from the requirement for a tolerance.
Case # and Name: 3074 Grotan (*)

DCI Number: GDCI-083301-29711

Footnotes: [The following notes are referenced in column two (5. Study File) of the REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE form.]Key:

United States Environmental Protection

Agency Washington, D.C. 20460

FOOTNOTES AND KEY DEFINITIONS FOR GUIDELINE REQUIREMENTS

MP; TGAI = Manufacturing Use Product; Technical Grade Active Ingredient; MP = Manufacturing Use Product [MP]; TGAI = Technical Grade Active Ingredient 

16 Studies which are designed to simultaneously fulfill the requirements of both the chronic oral and carcinogenicity studies (i.e. a combined study under Gu17 Studies which are designed to simultaneously fulfill the requirements of both the chronic oral and carcinogenicity studies (i.e. a combined study under Gu18 If the requirement for a carcinogenicity study in any species is modified or waived for any reason, then a subchronic 90-day oral study in the same specie

Guideline 870.3100, may be required to evaluate potential to produce preneoplastic lesions.

19 If the requirement for a carcinogenicity study in any species is modified or waived for any reason, then a subchronic 90-day oral study in the same specie

Guideline 870.3100, may be required to evaluate potential to produce preneoplastic lesions.

20 For low exposure antimicrobials, a carcinogenicity study in two species is required if any of the following criteria are met: (i) The weight of evidence indi

ingredient or any of its metabolites, transformation products or impurities based upon consideration of whether the substance: (A) Is structurally related mutagenic effects as demonstrated by in vitro or in vivo testing. (C) Produces a morphologic effect in any organ (e.g., hyperplasia, metaplasia) in subchrchange. (ii) Use of the pesticide product is likely to result inhuman exposure over a substantial portion of the human life span which is significant in terms of the frequency, magnitude, or duration of exposure.

21 For low exposure antimicrobials, a carcinogenicity study in two species is required if any of the following criteria are met: (i) The weight of evidence indi

ingredient or any of its metabolites, transformation products or impurities based upon consideration of whether the substance: (A) Is structurally related mutagenic effects as demonstrated by in vitro or in vivo testing. (C) Produces a morphologic effect in any organ (e.g., hyperplasia, metaplasia) in subchrchange. (ii) Use of the pesticide product is likely to result inhuman exposure over a substantial portion of the human life span which is significant in terms of the frequency, magnitude, or duration of exposure.

22 The Agency will require application exposure data beyond the required product use information (Guideline 875.1700) if at least one of the following expo

following toxicity criteria are met by the TEP, TGAI, or one of the pesticide's metabolites: (i) Exposure criteria. (A) Dermal exposure is likely to occur durto occur during use. (C) Adequate surrogate exposure data (e.g. PHED) to estimate the magnitude of exposure for a particular work activity with an acceunavailable. (ii) Toxicity criteria. (A) The acute dermal LD50 is less than or equal to 200 mg/kg (i.e., Toxicity Category I (Guideline 870.1200) as per 40 LC50 (Guideline 870.1300) is less than or equal to 0.05 mg/liter (i.e., 4-hour exposure, Toxicity Category I) and the TGAI has a vapor pressure greater thoutdoors or any indoor application regardless of the vapor pressure. (C) The pesticide is found to be a neurotoxicant (Guideline 870.6200). (D) The pesttoxicant (Guidelines 870.3700 and 870.6300). (E) The pesticide is found to be a carcinogen (Guideline 870.4200). (F) The pesticide shows potential adas 90-day oral (Guideline 870.3100), 21-day repeated dermal toxicity (Guideline 870.3200), 90-day dermal toxicity (Guideline 870.3250), 90-day inhalatand fertility effects (Guideline 870.3800), and chronic feeding (Guideline 870.4100). (G) The pesticide is found to be a mutagen (Guidelines 870.5100 to (Guideline 870.7800). (H) Epidemiological or poisoning incidence data indicate adverse effects from handling the pesticide.

23 Required for outdoor uses when that is the primary use or if outdoor uses are expected to result in greater exposure than indoor uses.

24 Protocols must be submitted to the Agency for approval before initiating a study.
Case # and Name: 3074 Grotan (*)

DCI Number: GDCI-083301-29711

Footnotes: [The following notes are referenced in column two (5. Study File) of the REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE form.]Key:

United States Environmental Protection

Agency Washington, D.C. 20460

FOOTNOTES AND KEY DEFINITIONS FOR GUIDELINE REQUIREMENTS

MP; TGAI = Manufacturing Use Product; Technical Grade Active Ingredient; MP = Manufacturing Use Product [MP]; TGAI = Technical Grade Active Ingredient 

25 The Agency will require application exposure data beyond the required product use information (Guideline 875.1700) if at least one of the following expo

following toxicity criteria are met by the TEP, TGAI, or one of the pesticide's metabolites: (i) Exposure criteria. (A) Dermal exposure is likely to occur durto occur during use. (C) Adequate surrogate exposure data (e.g. PHED) to estimate the magnitude of exposure for a particular work activity with an acceunavailable. (ii) Toxicity criteria. (A) The acute dermal LD50 is less than or equal to 200 mg/kg (i.e., Toxicity Category I (Guideline 870.1200) as per 40 LC50 (Guideline 870.1300) is less than or equal to 0.05 mg/liter (i.e., 4-hour exposure, Toxicity Category I) and the TGAI has a vapor pressure greater thoutdoors or any indoor application regardless of the vapor pressure. (C) The pesticide is found to be a neurotoxicant (Guideline 870.6200). (D) The pesttoxicant (Guidelines 870.3700 and 870.6300). (E) The pesticide is found to be a carcinogen (Guideline 870.4200). (F) The pesticide shows potential adas 90-day oral (Guideline 870.3100), 21-day repeated dermal toxicity (Guideline 870.3200), 90-day dermal toxicity (Guideline 870.3250), 90-day inhalatand fertility effects (Guideline 870.3800), and chronic feeding (Guideline 870.4100). (G) The pesticide is found to be a mutagen (Guidelines 870.5100 to (Guideline 870.7800). (H) Epidemiological or poisoning incidence data indicate adverse effects from handling the pesticide.

26 Protocols must be submitted to the Agency for approval before initiating a study.27 Required for indoor uses such as aquaria when the Agency determines such uses are likely to result in greater exposure than outdoor uses.

28 The Agency will require application exposure data beyond the required product use information (Guideline 875.1700) if at least one of the following expo

following toxicity criteria are met by the TEP, TGAI, or one of the pesticide's metabolites: (i) Exposure criteria. (A) Dermal exposure is likely to occur durto occur during use. (C) Adequate surrogate exposure data (e.g. PHED) to estimate the magnitude of exposure for a particular work activity with an acceunavailable. (ii) Toxicity criteria. (A) The acute dermal LD50 is less than or equal to 200 mg/kg (i.e., Toxicity Category I (Guideline 870.1200) as per 40 LC50 (Guideline 870.1300) is less than or equal to 0.05 mg/liter (i.e., 4-hour exposure, Toxicity Category I) and the TGAI has a vapor pressure greater thoutdoors or any indoor application regardless of the vapor pressure. (C) The pesticide is found to be a neurotoxicant (Guideline 870.6200). (D) The pesttoxicant (Guidelines 870.3700 and 870.6300). (E) The pesticide is found to be a carcinogen (Guideline 870.4200). (F) The pesticide shows potential adas 90-day oral (Guideline 870.3100), 21-day repeated dermal toxicity (Guideline 870.3200), 90-day dermal toxicity (Guideline 870.3250), 90-day inhalatand fertility effects (Guideline 870.3800), and chronic feeding (Guideline 870.4100). (G) The pesticide is found to be a mutagen (Guidelines 870.5100 to (Guideline 870.7800). (H) Epidemiological or poisoning incidence data indicate adverse effects from handling the pesticide.

29 Required for outdoor uses when that is the primary use or if outdoor uses are expected to result in greater exposure than indoor uses.

30 Protocols must be submitted to the Agency for approval before initiating a study.
Case # and Name: 3074 Grotan (*)

DCI Number: GDCI-083301-29711

Footnotes: [The following notes are referenced in column two (5. Study File) of the REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE form.]Key:

United States Environmental Protection

Agency Washington, D.C. 20460

FOOTNOTES AND KEY DEFINITIONS FOR GUIDELINE REQUIREMENTS

MP; TGAI = Manufacturing Use Product; Technical Grade Active Ingredient; MP = Manufacturing Use Product [MP]; TGAI = Technical Grade Active Ingredient 

Use Categories Key:

M - X - 

Indoor nonfood useMaterials preservatives

31 The Agency will require application exposure data beyond the required product use information (Guideline 875.1700) if at least one of the following expo

following toxicity criteria are met by the TEP, TGAI, or one of the pesticide's metabolites: (i) Exposure criteria. (A) Dermal exposure is likely to occur durto occur during use. (C) Adequate surrogate exposure data (e.g. PHED) to estimate the magnitude of exposure for a particular work activity with an acceunavailable. (ii) Toxicity criteria. (A) The acute dermal LD50 is less than or equal to 200 mg/kg (i.e., Toxicity Category I (Guideline 870.1200) as per 40 LC50 (Guideline 870.1300) is less than or equal to 0.05 mg/liter (i.e., 4-hour exposure, Toxicity Category I) and the TGAI has a vapor pressure greater thoutdoors or any indoor application regardless of the vapor pressure. (C) The pesticide is found to be a neurotoxicant (Guideline 870.6200). (D) The pesttoxicant (Guidelines 870.3700 and 870.6300). (E) The pesticide is found to be a carcinogen (Guideline 870.4200). (F) The pesticide shows potential adas 90-day oral (Guideline 870.3100), 21-day repeated dermal toxicity (Guideline 870.3200), 90-day dermal toxicity (Guideline 870.3250), 90-day inhalatand fertility effects (Guideline 870.3800), and chronic feeding (Guideline 870.4100). (G) The pesticide is found to be a mutagen (Guidelines 870.5100 to (Guideline 870.7800). (H) Epidemiological or poisoning incidence data indicate adverse effects from handling the pesticide.

32 Required for outdoor uses when that is the primary use or if outdoor uses are expected to result in greater exposure than indoor uses.

33 Protocols must be submitted to the Agency for approval before initiating a study.34 Required for indoor uses such as aquaria when the Agency determines such uses are likely to result in greater exposure than outdoor uses.35 Data reporting and calculations are required when exposure data are submitted.36 The required description of human activity data include data such as frequency and duration of exposure to evaluate the potential differences in exposur

and children), and to determine how specific postapplication activity patterns affect exposure levels.

37 Data reporting and calculations are required when exposure data are submitted.38 Use information pertains to the methods of mixing, loading and applying the pesticide and associated work practices that will play an integral part in dete

pesticide handlers. Required product use information includes range and typical values for: Application rates; area treated per day and per year; timing aper year for private and professional handlers; exposure time per activity; types of handling equipment; type of clothing worn; geographical distribution of 

39 Required product use information includes reapplication rates and frequencies, re-entry intervals, rinsing and other residue removal practices, and any o

application.

40 Data are required for both dermal and inhalation exposure.
United States Environmental Protection

Agency Washington, D.C. 20460

LIST OF ALL REGISTRANTS SENT THIS DATA CALL-IN NOTICE

Co. Nr. Company Name Agent For Address City & S

Case # and Name: 3074,Grotan (*)

TROY CHEMICAL COMPANYLIMITED

365 LEWIS & HARRISON 122 C ST NW STE 740 WASHIN

INTERNATIONAL SPECIALTYPRODUCTS

1529 1361 ALPS RD. WAYNE 1839 STEPAN COMPANY 22 W. FRONTAGE RD. NORTH33753 BASF CORPORATION 100 CAMPUS DRIVE FLORHA1258 ARCH CHEMICALS, INC. 5660 NEW NORTHSIDE DRIVE, N.W., SUITE 1100 ATLANT